Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy

被引：0

作者：

Strati, Paolo ^{[1
]}

Brandt, Amanda ^{[2
]}

Henderson, Jared ^{[3
]}

Westin, Jason ^{[1
]}

Nastoupil, Loretta J. ^{[2
]}

Al Zaki, Ajlan ^{[4
]}

Jallouk, Andrew P. ^{[5
]}

Adkins, Sherry

Shpall, Elizabeth J. ^{[6
]}

Kebriaei, Partow ^{[6
]}

Ramdial, Jeremy ^{[6
]}

Saini, Neeraj Y. ^{[6
]}

Ahmed, Sairah ^{[7
]}

Flowers, Christopher R. ^{[1
]}

Neelapu, Sattva S. ^{[1
]}

Hildebrandt, Michelle ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Lymphoma Myeloma, Houston, TX 77030 USA

[5] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma & Stem Cell Transplantat, Houston, TX 77030 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180744

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Liu, Wei
Huang, Wenyang
Lv, Ryu
Deng, Shuhui
Yi, Shuhua
Liu, Huimin
Lv, Lulu
Qiu, Lugui
Zou, Dehui
Wang, Jianxiang
BLOOD, 2020, 136
[42] Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma
Strati, Paolo
Ahmed, Sairah
Kebriaei, Partow
Nastoupil, Loretta J.
Claussen, Catherine M.
Watson, Grace
Horowitz, Sandra B.
Brown, Anne Rain T.
Do, Bryan
Rodriguez, Maria A.
Nair, Ranjit
Shpall, Elizabeth J.
Green, Michael R.
Neelapu, Sattva S.
Westin, Jason R.
BLOOD ADVANCES, 2020, 4 (13) : 3123 - 3127
[43] Long-Term Follow-Up of Anti-CD19 CAR T-Cell Therapy for B-Cell Lymphoma and Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 8 - 9
[44] Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma A Review
Locke, Frederick L.
Go, William Y.
Neelapu, Sattva S.
JAMA ONCOLOGY, 2020, 6 (02) : 281 - 290
[45] CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma
Schubert, Maria-Luisa
Dreger, Peter
LANCET, 2024, 404 (10450): : 314 - 315
[46] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
Zhang, Wen-ying
Liu, Yang
Wang, Yao
Nie, Jing
Guo, Ye-lei
Wang, Chun-meng
Dai, Han-ren
Yang, Qing-ming
Wu, Zhi-qiang
Han, Wei-dong
GENE THERAPY, 2018, 25 (03) : 198 - 204
[47] Molecular disease monitoring in patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving anti-CD19 CAR T-cell therapy.
Colton, Meryl D.
Purev, Enkhtsetseg
Haverkos, Bradley
Bair, Steven Michael
Jasem, Jagar
Schliekelman, Mark Jason
Kamdar, Manali K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma
Abramson, Jeremy S.
McGree, Brianne
Noyes, Sarah
Plummer, Sean
Wong, Curtis
Chen, Yi-Bin
Palmer, Edwin
Albertson, Tina
Ferry, Judith A.
Arrillaga-Romany, Isabel C.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (08): : 783 - 784
[49] Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy
Wen-ying Zhang
Yang Liu
Yao Wang
Jing Nie
Ye-lei Guo
Chun-meng Wang
Han-ren Dai
Qing-ming Yang
Zhi-qiang Wu
Wei-dong Han
Gene Therapy, 2018, 25 : 198 - 204
[50] CAR T-cell therapy for B-cell lymphoma
Denlinger, Nathan
Bond, David
Jaglowski, Samantha
CURRENT PROBLEMS IN CANCER, 2022, 46 (01)

← 1 2 3 4 5 →